JPH07507440A - 結合親和性を高めた抗体構築物 - Google Patents

結合親和性を高めた抗体構築物

Info

Publication number
JPH07507440A
JPH07507440A JP3505551A JP50555191A JPH07507440A JP H07507440 A JPH07507440 A JP H07507440A JP 3505551 A JP3505551 A JP 3505551A JP 50555191 A JP50555191 A JP 50555191A JP H07507440 A JPH07507440 A JP H07507440A
Authority
JP
Japan
Prior art keywords
construct
antibody
region
binding
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP3505551A
Other languages
English (en)
Japanese (ja)
Inventor
ジリーズ，スティーヴン・ディー
Original Assignee
レプリゲン・コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by レプリゲン・コーポレーション filed Critical レプリゲン・コーポレーション
Publication of JPH07507440A publication Critical patent/JPH07507440A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP3505551A 1990-03-02 1991-01-30 結合親和性を高めた抗体構築物 Pending JPH07507440A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US488,297 1983-04-25
US48829790A 1990-03-02 1990-03-02
PCT/US1991/000633 WO1991013166A1 (en) 1990-03-02 1991-01-30 Antibody constructs with enhanced binding affinity

Publications (1)

Publication Number Publication Date
JPH07507440A true JPH07507440A (ja) 1995-08-24

Family

ID=23939159

Family Applications (1)

Application Number Title Priority Date Filing Date
JP3505551A Pending JPH07507440A (ja) 1990-03-02 1991-01-30 結合親和性を高めた抗体構築物

Country Status (4)

Country Link
EP (1) EP0517754A1 (de)
JP (1) JPH07507440A (de)
CA (1) CA2077348A1 (de)
WO (1) WO1991013166A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0574395T3 (da) * 1990-11-09 2002-10-07 Stephen D Gillies Cytokin-immunkonjugater
US5650150A (en) * 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
US7026446B1 (en) * 1997-12-24 2006-04-11 Diatech Pty Ltd. Bifunctional molecules
CN1235911C (zh) 1999-08-09 2006-01-11 利思进药品公司 多细胞因子－抗体复合物
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
KR20090010127A (ko) * 2001-03-07 2009-01-28 메르크 파텐트 게엠베하 하이브리드 이소타입 항체 부분구조를 포함하는 단백질을 위한 발현 기술
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
AU2004273791A1 (en) * 2003-09-05 2005-03-31 Genentech, Inc. Antibodies with altered effector functions
PT1706428E (pt) 2004-01-22 2009-12-29 Merck Patent Gmbh Anticorpos anticancerígenos com fixação de complemento reduzida
DK1912675T3 (en) 2005-07-25 2014-03-24 Emergent Product Dev Seattle B-cell reduction using specific and cd37-cd20-specific binding molecules
AU2006332155B2 (en) 2005-12-30 2013-01-10 Cancer Research Technology Limited Anti-CD19 antibodies with reduced immunogenicity
ATE555125T1 (de) 2005-12-30 2012-05-15 Merck Patent Gmbh Interleukin-12p40-varianten mit verbesserter stabilität
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
JP6013733B2 (ja) 2008-04-11 2016-10-25 エマージェント プロダクト デベロップメント シアトル， エルエルシー Ｃｄ３７免疫治療薬および二機能性化学療法薬とのその組合せ
EA201171259A1 (ru) 2009-04-22 2012-05-30 Мерк Патент Гмбх Антительные гибридные белки с модифицированными сайтами связывания fcrn
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
JP7002446B2 (ja) 2015-09-21 2022-03-04 アプティーボ リサーチ アンド デベロップメント エルエルシー Ｃｄ３結合ポリペプチド
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE143052T1 (de) * 1986-07-07 1996-10-15 Centocor Inc Chimärisches murine-mensch-immunoglobulin, spezifisch für tumorassoziertes 17-1a antigen

Also Published As

Publication number Publication date
EP0517754A1 (de) 1992-12-16
WO1991013166A1 (en) 1991-09-05
CA2077348A1 (en) 1991-09-03

Similar Documents

Publication Publication Date Title
JPH07507440A (ja) 結合親和性を高めた抗体構築物
US6174691B1 (en) Minimum recognition unit of a PEM mucin tandem repeat specific monoclonal antibody
Brown et al. Tumor-specific genetically engineered murine/human chimeric monoclonal antibody
US6071515A (en) Dimer and multimer forms of single chain polypeptides
Adams et al. Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erb B-2 single-chain Fv
US5534254A (en) Biosynthetic binding proteins for immuno-targeting
Mueller et al. Serum half-life and tumor localization of a chimeric antibody deleted of the CH2 domain and directed against the disialoganglioside GD2.
US8617846B2 (en) Tumor-specific recognition molecules
Xu et al. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein
JP3492373B2 (ja) モノクローナル抗体
US20030147808A1 (en) Single Chain Fv constructs of anti-ganglioside GD2 antibodies
JPH09500381A (ja) トランスフェリン受容体特異的リガンド−神経作用剤融合タンパク質
US11642418B2 (en) Use of radiolabeled nanobody in prognosis and diagnosis of cancer
Crombet et al. Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor in advanced brain tumor patients: preliminary study
US20070042447A1 (en) Use of anti-ferritin monoclonal antibodies in the treatment of some cancers (divisional)
US6737064B2 (en) Method for the diagnosis of neoplastic tissue comprising administering a vasopermeability enhancing peptide of human interleukin-2
US6534479B1 (en) Recombinant alpha-fetoprotein hybrid cytotoxins for treating and diagnosing cancers
US20190023785A1 (en) MONOCLONAL ANTIBODY FnAb8 AND APPLICATION THEREOF
TWI602577B (zh) 雙重標靶融合蛋白
Li et al. Development and characterization of the recombinant human VEGF-EGF dual-targeting fusion protein as a drug delivery system
JP2004507205A (ja) Ｃａ１９−９抗原陽性細胞の検出および除去のためのポリペプチド
US6440386B1 (en) Stabilized radiophosphate-labeled proteins
AU644413B2 (en) Antibody constructs with enhanced binding affinity
ES2218717T3 (es) Peptido portenciador de la vasopermeabilidad de la interleuquina-2 humana e inmunoconjugados del mismo.
US20040156824A1 (en) Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof